Our assessment
MEDVi puts a compounded injection, a compounded tablet and a brand-name product on one page with figures attached to all three. Very few sellers here let you compare a tablet and an injection that directly. The problem is what the compounded figures are labeled: GLP-1, and nothing more, so you can't tell which molecule your money buys. Several of its FAQ answers also repeat the same unrelated sentence.
A tablet and an injection, priced together
MEDVi publishes a starting figure for a compounded GLP-1 injection and a separate, higher one for a compounded GLP-1 tablet.
MEDVi publishes prices for an oral tablet and an injection on the same page, making its advertised format prices easy to compare.
The tablet has a higher advertised price than the injection. Compare the exact active ingredient, formulation and plan terms rather than assuming the price difference reflects equivalent treatments.
The compound behind the price is not stated
MEDVi labels both compounded figures as GLP-1 rather than as semaglutide or tirzepatide. Its customer stories mention both compounds, so both appear to be available.
What's missing is the link between a compound and a price. If you want tirzepatide, the page won't tell you whether the published figure buys it, or what switching would cost.
That also means these figures can't be set like for like against sellers that price each compound separately. Ask which compound the figure covers before you treat it as your rate.
A brand-name option at a large cash figure
MEDVi lists brand-name Ozempic with its own published cash figure, one of the two highest brand-name numbers on these boards — FeelGood publishes the same amount for a product it does not name.
Publishing it at all is worth something. Several sellers route the brand-name question into an intake instead, so the gap between compounded and brand-name stays invisible until you have already enrolled.
It is a cash price, not an estimate of what a plan would charge. If you have coverage, the number to compare it against is your own plan's.
Straight talk in one place, filler in another
MEDVi states plainly that compounded GLP-1s are not FDA-approved and have not been evaluated for safety or effectiveness, and that MEDVi does not produce them. That is clearer than several competitors manage.
Its terms are specific too, naming the company, its Delaware address, and the clinical groups that provide medical treatment through the platform.
The FAQ is the weak spot. Several different questions, including what the program costs, are answered with the same sentence about serving patients across multiple states. Those answers aren't really published, so treat them as questions to ask rather than questions answered.
What is not published
MEDVi describes its pharmacy partners as multiple certified US pharmacies and names none of them. That is the same limit most of this field has.
No list of served states appears anywhere on the site. The only availability language is that FAQ line about multiple states — the same sentence used to answer four other questions.
The catalog itself is small. One product page carries the entire GLP-1 offering, so what is on that page is what MEDVi publishes.
MEDVi's published pricing
Prices re-verified September 2026
| Medication | Price |
|---|---|
| MedicationGlp-1 (compounded) — injection, starting figure | Price$179/mostarting price, per month; the site doesn't specify which compound this figure covers |
| MedicationGlp-1 (compounded-oral) — tablet, starting figure | Price$249/mostarting price, per month; the site doesn't specify which compound this figure covers |
| MedicationSemaglutide (brand) — Ozempic | Price$1,999/mostarting price, per month |
Compare GLP may earn a commission when a reader signs up with a provider through a link on this site. 28 of the 420 providers reviewed here are paid partners today; the other 392 are not. See how this works.
See MEDVi's current price →Who MEDVi suits
Good fit if
- Readers comparing a compounded tablet against a compounded injection at published starting figures.
- Patients who want a brand-name cash figure printed rather than held back until intake.
- People who value a seller stating plainly that compounded medication is not FDA-approved.
- Readers who want the operating company, its address and its clinical partners all named in the terms.
Look elsewhere if
- Anyone comparing semaglutide against tirzepatide on price, since MEDVi labels both compounded figures only as GLP-1.
- Readers who need the compounding pharmacy named. MEDVi describes multiple certified partners without naming one.
- Patients who need their state confirmed from the site, since no list of served states is published anywhere on it.
- Anyone relying on the FAQ for basic answers, since several questions there are answered with the same unrelated sentence.
What stands out about MEDVi
Strengths
- Offers a compounded tablet as well as a weekly injection, and prices both on the same page
- Publishes a cash figure for brand-name Ozempic rather than routing the question into an intake
- The operating entity, its address and the clinical groups behind the prescriptions are all named in the terms
- States plainly that compounded GLP-1s are not FDA-approved and that MEDVi does not produce them
Trade-offs
- Both compounded figures are labeled only as GLP-1, so a reader cannot tell whether a price is for semaglutide or tirzepatide before starting an intake
- The compounding pharmacies are described as multiple certified partners and are not named
- The FAQ section repeats one answer about serving multiple states under every question, including the question about cost, so several basic answers are not actually published
- No list of served states appears anywhere on the site
How this review was verified
- MEDVi's sitemap lists eleven URLs, one of them a product page. That single page carries the whole GLP-1 offering.
- All three published figures come from that product page, each read on the date shown.
- Both compounded figures are labeled GLP-1. Neither is tied to semaglutide or tirzepatide anywhere on the page.
- The live domain, the operating company, its Delaware address and the named clinical groups all come from MEDVi's own terms.
- The same answer, a sentence about serving patients across multiple states, appears under several different FAQ questions, including the one about program cost.
Where MEDVi ranks
MEDVi qualifies for 4 of the 6 boards on this site. A board only ranks the providers that meet its own condition, so a missing board means MEDVi does not publish what that board sorts on.
- Semaglutide — #206 of 334
- Cheapest Overall — #206 of 396
- Brand-Name Available — #83 of 88
- Oral — #64 of 108
Compare MEDVi directly
Compare GLP may earn a commission when a reader signs up with a provider through a link on this site. 28 of the 420 providers reviewed here are paid partners today; the other 392 are not. See how this works.
| Provider | Score | From/mo | Full review | Action |
|---|---|---|---|---|
| Belle Health | 10.0/10 | From/mo$109Advertised monthly equivalent for a twelve-month supply; not a verified monthly installment. Six-month rate $119, two-month rate $135, one-month rate $199. Confirm the upfront payment and refill schedule. | Full reviewRead the Belle Health review | Visit |
| Midi Health | 10.0/10 | From/mo$164for a 4-week supply, the lowest of four published dose tiers, including shipping | Full reviewRead the Midi Health review | Visit |
| altRx | 8.6/10 | From/mo$89/moadvertised monthly starting price for a multi-dose vial; confirm plan length and checkout total | Full reviewRead the altRx review | Visit |
Frequently asked questions
Is the published price for semaglutide or tirzepatide?
MEDVi doesn't say. Both compounded figures are labeled only as GLP-1, one for an injection and one for a tablet. Customer stories on the same page mention both compounds, so both appear to be available, but no figure is tied to either. Ask which compound your quote covers before treating the published number as your rate.
Why does the tablet cost more than the injection?
MEDVi lists the tablet at a higher price. The reviewed pages do not explain the difference; confirm the medication and supply duration before comparing it with another formulation.
Can I get a brand-name GLP-1 through MEDVi?
MEDVi publishes a cash figure for brand-name Ozempic, one of the two highest brand-name numbers on these boards. It is a cash price rather than what a plan would charge, so if you have coverage, compare it against your own plan. Publishing it at all is still useful, since several sellers hide the brand-name question behind an intake.
The FAQ did not answer my question. Why?
Several questions in MEDVi's FAQ share one answer, a sentence about serving patients across multiple states. That sentence appears under the cost question too. Take those questions to MEDVi directly rather than assuming the site has addressed them.
Does MEDVi ship to my state?
Confirm it directly. No list of served states appears anywhere on the site, and the only availability language is that repeated FAQ sentence about multiple states. MEDVi is specific about its company and its clinical partners in the terms, so the gap is in what it publishes about coverage, not in who it is.
Ready to compare directly?
MEDVi scores 4.3/10 on this site's rubric. Review the published prices and their conditions above, then confirm your total with the provider. Visiting its site does not commit you to treatment.
Compare GLP may earn a commission when a reader signs up with a provider through a link on this site. 28 of the 420 providers reviewed here are paid partners today; the other 392 are not. See how this works.
Visit MEDVi →